OKLAHOMA CITY, Sept. 28, 2017 -- Federman & Sherwood announces that on September 27, 2017, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is May 31, 2016 through September 20, 2017.
Plaintiff seeks to recover damages on behalf of all Intercept Pharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, November 27, 2017 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.
If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:
Robin Hester
FEDERMAN & SHERWOOD
10205 North Pennsylvania Avenue
Oklahoma City, OK 73120
Email to: [email protected]
Or, visit the firm’s website at www.federmanlaw.com


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Instagram Outage Disrupts Thousands of U.S. Users
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



